NOVOCURE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.64 USD | +3.31% |
|
+4.51% | -15.37% |
| Sales 2024 * | 538M 43.09B | Sales 2025 * | 581M 46.48B | Capitalization | 1.36B 109B |
|---|---|---|---|---|---|
| Net income 2024 * | -189M -15.13B | Net income 2025 * | -203M -16.25B | EV / Sales 2024 * | 2.65 x |
| Net Debt 2024 * | 67.93M 5.44B | Net Debt 2025 * | 234M 18.74B | EV / Sales 2025 * | 2.74 x |
| P/E ratio 2024 * |
-7.19
x | P/E ratio 2025 * |
-6.89
x | Employees | 1,453 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.74% |
More Fundamentals
* Assessed data
More news
Latest transcript on NovoCure Limited
More recommendations
More press releases
More news
| 1 day | +3.31% | ||
| 1 week | +4.51% | ||
| Current month | -19.16% | ||
| 1 month | -13.70% | ||
| 3 months | -11.08% | ||
| 6 months | -0.04% | ||
| Current year | -15.37% |
1 week
11.70
12.65
1 month
11.7015.63
Current year
11.7018.04
1 year
10.8783.60
3 years
10.87232.76
5 years
10.87232.76
10 years
5.95232.76
| Managers | Title | Age | Since |
|---|---|---|---|
Asaf Danziger
CEO | Chief Executive Officer | 56 | 31/12/01 |
Ashley Cordova
DFI | Director of Finance/CFO | 45 | 31/05/14 |
Moshe Giladi
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Doyle
CHM | Chairman | 61 | 31/12/03 |
Kin Yip Leung
BRD | Director/Board Member | 62 | 04/08/11 |
David Hung
BRD | Director/Board Member | 66 | 30/05/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.81% | 0 M€ | 0.00% | - | |
| 0.71% | 0 M€ | 0.00% | - | |
| 0.19% | 18 M€ | +3.79% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 12.64 | +3.31% | 762,109 |
| 25/04/24 | 12.23 | -0.89% | 1,152,169 |
| 24/04/24 | 12.34 | +2.36% | 1,317,018 |
| 23/04/24 | 12.06 | +1.90% | 839,660 |
| 22/04/24 | 11.83 | -2.15% | 809,482 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Calendar
02/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
12.64
USD
Average target price
26.17
USD
Spread / Average Target
+107.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.37% | 1.36B | |
| +73.17% | 12.38B | |
| -18.74% | 7.92B | |
| +16.15% | 7.2B | |
| +4.81% | 5.84B | |
| +5.99% | 5.07B | |
| +27.07% | 4.53B | |
| -21.67% | 3.88B | |
| -40.82% | 2.23B | |
| +1.49% | 2.02B |
- Stock Market
- Equities
- NVCR Stock
